IPD
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

ImpediMed Limited is a medical technology company that develops, manufactures, and sells non-invasive bioimpedance spectroscopy (BIS) systems and software services. The company’s primary product, the SOZO Digital Health Platform, is used for the early detection and monitoring of fluid status and tissue composition, with a specific focus on the early detection of lymphoedema, particularly breast cancer-related lymphoedema. The platform also supports clinical applications in body composition analysis, heart failure management, and protein calorie malnutrition assessment. ImpediMed serves healthcare providers and patients in the United States, Europe, and Australia, with a significant installed base in North America and a distribution partnership in Australia. The company’s products are FDA-cleared, CE-marked, and ARTG-listed, and the SOZO platform includes specific analysis modules such as L-Dex for lymphoedema, BodyComp for tissue composition, and HF-Dex for heart failure monitoring.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Health Care Equipment & Services Homepage impedimed.com
Sector Healthcare IR page investors.impedimed.com
Tags
bioimpedance spectroscopy, lymphoedema, fluid status monitoring, tissue composition, heart failure, body composition, digital health platform, oncology, non-invasive diagnostics, SOZO, L-Dex, BodyComp, HF-Dex
Press page impedimed.com/about/newsroom

Metrics

Valuation  
Market cap A$ 14.664M
P/E -50.00
P/BV 1.80
P/S 1.00
P/OCF -0.82
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC -60.6%
Profit margin —
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -9.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 14.613M 12.724M 10.319M — — — — — — — — — 3.578M 2.925M
Net profit — — — — — — — — — — — — -7.935M -8.464M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 0.01 0.04 0.07 0.18 0.06 0.11 — — — — — — — —
Price performance 12m -0.83 -0.51 -0.61 1.95 -0.42 — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

ImpediMed Limited (ticker IPD), listed in Australia.